DK3186244T3 - DIOXOLANALOGS OF URIDINE FOR THE CANCER OF CANCER - Google Patents

DIOXOLANALOGS OF URIDINE FOR THE CANCER OF CANCER Download PDF

Info

Publication number: DK3186244T3
Authority: DK; Denmark
Prior art keywords: cancer; dioxolanalogs; uridine
Prior art date: 2014-08-25

Application number

DK15756888.2T

Other languages

Danish (da)

Inventor

Anders Eneroth

Björn Klasson

Fredrik ÖBERG

Richard Bethell

Original Assignee

Medivir Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-25

Filing date

2015-08-24

Publication date

2020-07-13

2015-08-24 Application filed by Medivir Ab filed Critical Medivir Ab

2020-07-13 Application granted granted Critical

2020-07-13 Publication of DK3186244T3 publication Critical patent/DK3186244T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

DK15756888.2T 2014-08-25 2015-08-24 DIOXOLANALOGS OF URIDINE FOR THE CANCER OF CANCER DK3186244T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE1450983		2014-08-25
SE1550858		2015-06-22
PCT/EP2015/069370 WO2016030335A1 (en)	2014-08-25	2015-08-24	Dioxolane analogues of uridine for the treatment of cancer

Publications (1)

Publication Number	Publication Date
DK3186244T3 true DK3186244T3 (en)	2020-07-13

Family

ID=54014804

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15756888.2T DK3186244T3 (en)	2014-08-25	2015-08-24	DIOXOLANALOGS OF URIDINE FOR THE CANCER OF CANCER
DK19177824.0T DK3572410T3 (en)	2014-08-25	2015-08-24	DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK19177824.0T DK3572410T3 (en)	2014-08-25	2015-08-24	DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER

Country Status (24)

Country	Link
US (7)	US10144750B2 (en)
EP (2)	EP3572410B1 (en)
JP (2)	JP6663424B2 (en)
KR (2)	KR102396905B1 (en)
CN (4)	CN111269264A (en)
AU (2)	AU2015308988C1 (en)
BR (1)	BR112017003898B1 (en)
CA (2)	CA3128645C (en)
CY (1)	CY1122945T1 (en)
DK (2)	DK3186244T3 (en)
EA (2)	EA031106B1 (en)
ES (2)	ES2927212T3 (en)
HR (1)	HRP20201023T1 (en)
HU (2)	HUE059640T2 (en)
IL (2)	IL250344B (en)
MX (1)	MX369649B (en)
MY (2)	MY188089A (en)
NZ (2)	NZ729118A (en)
PH (2)	PH12017500184A1 (en)
PL (2)	PL3572410T3 (en)
PT (2)	PT3186244T (en)
SG (3)	SG11201701172SA (en)
WO (1)	WO2016030335A1 (en)
ZA (1)	ZA201802864B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE059640T2 (en) *	2014-08-25	2022-12-28	Medivir Ab	Dioxolane analogues of uridine for the treatment of cancer
CN106543220A (en) *	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	Phosphoramidate compounds and preparation method thereof and crystal
CN108779136B (en)	2015-12-11	2022-07-08	努卡那有限公司	Diastereoselective Synthesis of Phosphate Derivatives and Gemcitabine Prodrug NUC-1031
CA3014769C (en) *	2016-03-02	2024-01-09	Medivir Aktiebolag	Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN106432328B (en) *	2016-09-14	2019-03-22	江苏福瑞生物医药有限公司	A kind of preparation method of Suo Feibuwei intermediate
MA46839A (en) *	2016-11-18	2021-03-24	Neurovive Pharmaceutical Ab	MEDICINAL PRODUCTS OF IONOPHORES OF MITOCHONDRIAL PROTONS
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
JP7337539B2 (en) *	2018-06-21	2023-09-04	メディヴィル・アクチエボラーグ	Base-Modified Cytidine Nucleotides for Leukemia Therapy
WO2019245444A1 (en)	2018-06-21	2019-12-26	Medivir Ab	Base-modified cytidine nucleotides for leukemia therapy
CA3129585A1 (en) *	2019-02-18	2020-08-27	Medivir Aktiebolag	Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
CN110964057B (en) *	2019-12-25	2022-05-06	东南大学	Method for preparing sofosbuvir intermediate by using microfluid reaction device
CN113402546A (en) *	2020-03-17	2021-09-17	浙江四维医药科技有限公司	Dynamic kinetic resolution method for tail chain of Rudesiwei phosphate intermediate
ES3027841T3 (en) *	2020-04-15	2025-06-17	Medivir Ab	Miv-818/lenvatinib combination therapy for liver cancer
CN113754692B (en) *	2020-06-03	2022-06-10	上海交通大学	Asymmetric catalytic synthesis of remdesivir intermediate (S,S)-phosphoramidate
CN114685558A (en) *	2020-12-28	2022-07-01	尚科生物医药（上海）有限公司	Preparation method of Reidesciclovir intermediate
CN114249764A (en) *	2021-11-10	2022-03-29	宁波大学	A kind of intermediate of phosphoramide ester prodrug and preparation method and application thereof
WO2025155547A1 (en) *	2024-01-17	2025-07-24	University Of Georgia Research Foundation, Inc.	An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5444063A (en) *	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6022876A (en)	1996-11-15	2000-02-08	Yale University	L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
PL361310A1 (en) *	2000-10-13	2004-10-04	Shire Biochem Inc.	Dioxolane analogs for improved inter-cellular delivery
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
WO2007106450A2 (en) *	2006-03-10	2007-09-20	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
US20100266674A1 (en)	2006-09-01	2010-10-21	University Of Georgia Research Foundation, Inc.	L-oddc prodrugs for cancer
PL216525B1 (en) *	2006-10-17	2014-04-30	Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk	5'-0-[(N-acyl) amidophosphate] - and 5'-0- [(N-acyl) amidothiophosphate]- and 5'-0- [N-acyl) amidodithiophosphate] and 5'-0- [N-acyl) amidoselenophosphate] - nucleosides and method for their manufacture
US20130143835A1 (en) *	2011-12-05	2013-06-06	Medivir Ab	HCV Polymerase Inhibitors
KR20160099090A (en) *	2013-11-27	2016-08-19	아이데닉스 파마슈티칼스 엘엘씨	Nucleotides for the treatment of liver cancer
HUE059640T2 (en) *	2014-08-25	2022-12-28	Medivir Ab	Dioxolane analogues of uridine for the treatment of cancer

2015
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/en unknown
- 2015-08-24 MX MX2017002328A patent/MX369649B/en active IP Right Grant
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 ES ES19177824T patent/ES2927212T3/en active Active
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 EA EA201790328A patent/EA031106B1/en not_active IP Right Cessation
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/en unknown
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/en active Pending
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/en active Active
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 ES ES15756888T patent/ES2796089T3/en active Active
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/en active Active
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/en active IP Right Grant
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/en active Active
- 2015-08-24 PT PT157568882T patent/PT3186244T/en unknown
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/en active Active
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/en active
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/en unknown
- 2015-08-24 PL PL15756888T patent/PL3186244T3/en unknown
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/en active Active
- 2015-08-24 EA EA201890648A patent/EA033300B1/en not_active IP Right Cessation
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/en active Active
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/en active
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/en unknown
- 2015-08-24 PT PT191778240T patent/PT3572410T/en unknown
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184A1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/en active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/en unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR112017003898A2 (en)	2017-12-05
CN110804072A (en)	2020-02-18
HRP20201023T1 (en)	2020-10-16
CN107074826B (en)	2020-05-22
IL266766B (en)	2020-05-31
IL250344B (en)	2020-01-30
AU2015308988B2 (en)	2018-04-26
PH12017500184B1 (en)	2017-06-28
US20190389890A1 (en)	2019-12-26
IL266766A (en)	2019-07-31
ZA201802864B (en)	2019-07-31
IL250344A0 (en)	2017-03-30
EP3572410B1 (en)	2022-07-20
CA2956251A1 (en)	2016-03-03
US10336780B2 (en)	2019-07-02
HUE050705T2 (en)	2020-12-28
NZ762628A (en)	2023-04-28
EP3186244A1 (en)	2017-07-05
ES2796089T3 (en)	2020-11-25
US20190100541A1 (en)	2019-04-04
US20170267705A1 (en)	2017-09-21
SG10201911558UA (en)	2020-01-30
SG10202001117YA (en)	2020-04-29
MY198325A (en)	2023-08-24
AU2015308988A1 (en)	2017-02-23
PH12019501919A1 (en)	2020-09-14
CN110790789B (en)	2023-05-12
US20200239502A1 (en)	2020-07-30
US10144750B2 (en)	2018-12-04
CN110790789A (en)	2020-02-14
CN110804072B (en)	2023-05-12
CN111269264A (en)	2020-06-12
MX2017002328A (en)	2017-05-22
US11447511B2 (en)	2022-09-20
SG11201701172SA (en)	2017-03-30
EA033300B1 (en)	2019-09-30
US10822360B2 (en)	2020-11-03
US10654877B2 (en)	2020-05-19
EA201890648A3 (en)	2019-02-28
CY1122945T1 (en)	2021-10-29
ES2927212T3 (en)	2022-11-03
CA2956251C (en)	2022-10-25
EA201790328A1 (en)	2017-08-31
CA3128645C (en)	2023-06-27
PH12017500184A1 (en)	2017-06-28
BR112017003898B1 (en)	2022-10-18
JP6663424B2 (en)	2020-03-11
AU2018201980B2 (en)	2019-05-16
JP2017526677A (en)	2017-09-14
JP2020090535A (en)	2020-06-11
KR20200035482A (en)	2020-04-03
PT3186244T (en)	2020-05-29
HUE059640T2 (en)	2022-12-28
EP3572410A1 (en)	2019-11-27
CA3128645A1 (en)	2016-03-03
EA201890648A2 (en)	2018-08-31
PL3572410T3 (en)	2022-10-03
PL3186244T3 (en)	2020-11-16
PT3572410T (en)	2022-09-15
DK3572410T3 (en)	2022-08-29
WO2016030335A1 (en)	2016-03-03
EP3186244B1 (en)	2020-04-22
MY188089A (en)	2021-11-17
NZ729118A (en)	2022-02-25
JP6905609B2 (en)	2021-07-21
AU2018201980A1 (en)	2018-04-12
EA031106B1 (en)	2018-11-30
AU2015308988C1 (en)	2018-09-06
CN107074826A (en)	2017-08-18
US20230382931A1 (en)	2023-11-30
KR20170046736A (en)	2017-05-02
KR102396905B1 (en)	2022-05-13
US20210054008A1 (en)	2021-02-25
US20230117570A1 (en)	2023-04-20
KR102398714B1 (en)	2022-05-17
MX369649B (en)	2019-11-15

Publication	Publication Date	Title
FIC20230006I1 (en)	2023-02-06	My vutrisiraani
DK3186244T3 (en)	2020-07-13	DIOXOLANALOGS OF URIDINE FOR THE CANCER OF CANCER
DK3283625T3 (en)	2020-03-02	NUCLEASE-MEDIED GENOMEDITING
DK3189082T3 (en)	2020-09-21	ANTI-PD-L1 CONJUGATES FOR THE TREATMENT OF TUMORS
DK3192902T3 (en)	2019-07-15	PROCEDURE FOR THE MANUFACTURE OF GRAPHENCY VISCOSEFIBREES
DK3331869T3 (en)	2021-02-15	MUSCARINAGONISTS
DK3277719T3 (en)	2022-05-02	POLYPEPTIDER
DK3331528T3 (en)	2021-10-25	MUSCARINAGONISTS
EP3316375A4 (en)	2019-03-06	REDOXDURCHFLUSSZELLE
PT3298027T (en)	2022-01-26	ANTELMINTHIC DEPSYPEPTIDE COMPOUNDS
DK3305788T3 (en)	2020-09-28	JANUS-KINASE-HIMMER
DK3360890T3 (en)	2020-11-02	GENTERAPHY
DK3331529T3 (en)	2021-10-18	MUSCARINAGONISTS
DK3310450T3 (en)	2019-08-05	OIL-WATER-SEPARATOR
EP3290364A4 (en)	2019-01-16	FÖRDERBANDVERSCHLEISSÜBERWACHUNGSSYSTEM
DK3270930T3 (en)	2021-10-04	PRE-CLAMPSY
EP3381654A4 (en)	2019-06-12	FLÜSSIGBLASFORMVERFAHREN
DK3394281T3 (en)	2020-11-09	GÆRCELLLE
EP3395436A4 (en)	2019-11-20	microreactor
EP3363322A4 (en)	2019-06-19	HAARVERLÄNGERER
LT3362444T (en)	2021-06-25	COMPOUNDS
DK3597189T3 (en)	2022-06-27	CRYSTALLINIC COMPOUNDS
DK3292136T3 (en)	2021-03-22	PENICILLIN-G-ACYLASER
DE112015006486A5 (en)	2018-01-04	Inkubationsrinne
DK3274482T3 (en)	2020-01-06	STENBORSKNOP